Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,935 total articles
Expand Energy (EXE) looks like an actionable long after management’s announced Twin Eagle acquisition (terms pending). The deal plugs a gap in gas marketing and LNG commercialization, complements strong cash generation, and sits against a valuation that reads cheaply: market cap ~$22.2B, P/E ~6.6, EV/EBITDA ~3.6. Trade plan: enter at $92.52, stop $…
Kyverna has cleared several clinical hurdles with statistically significant registrational results in stiff person syndrome and is advancing miv-cel across other autoimmune indications. Reports of an ElevateBio manufacturing tie-up (treated here as a conditional catalyst) combined with improving commercial-readiness metrics materially de-risk near-…
Cenovus (CVE) looks positioned to convert elevated commodity prices into cash that flows to the bottom line. With Q2 results and a bullish technical backdrop, the stock offers a defined risk-reward swing: enter at $29.06, stop $26.50, target $33.50 over a mid-term 45 trading day window.
Nvidia remains the clear leader in AI accelerators and data-center GPUs. Recent pullbacks have trimmed momentum but not the structural drivers: >80% share in AI data-center GPUs, massive free cash flow, and continued product expansion into CPUs and networking. I outline a tactical long trade with a clear entry, stop and target and explain the catal…
Coherus Oncology ($CHRS) is a low-priced, catalyst-rich microcap trading at roughly $1.44 with a market cap near $227M. Management has recently raised ~$50M, advanced a Phase 1 collaboration for LOQTORZI combinations, and set an earnings call for 08/05/2026. Given the cash infusion, a lighter enterprise value (~$144M), and heavy short interest, the…
Bandwidth (BAND) gapped sharply from $52.25 to the $38 area and is trading oversold with RSI ~28. The combination of meaningful free cash flow ($79.4M), enterprise adoption commentary, attractive EV/Sales (~2.3) and a large end-market tailwind for CPaaS argues for buying this dip. Enter at $37.80 with a $33 stop and a $52 target on a mid-term (45 t…
Micron plunged in late July on macro and geopolitical fear, but fundamentals tied to AI data-center memory demand remain supportive. The setup offers a defined-risk entry with upside to prior highs if pricing and capacity tightness persist.
SK hynix is deeply exposed to the AI-driven memory squeeze that has lifted chipmakers' profits. The stock has pulled back sharply from its highs; this trade idea outlines an actionable long with a clear entry at $127.00, a stop at $119.00 and a first target at $165.00 over a mid-term horizon (45 trading days). The plan leans on recent earnings stre…
<p>BillionToOne (BTO) is a clinical genomics company with a credible long-term story around non-invasive genetic testing, but near-term guidance and commercialization pace appear conservative while the equity looks priced for a faster ramp. That divergence creates a defined-reward short opportunity for disciplined traders willing to carry execution…
Electrovaya (ELVA) has been knocked around this year, but two facts have changed the risk-reward for me: a financed plan to secure manufacturing capacity and improving short interest dynamics. I’m doubling my target to $15.40 and taking a long position with a clear stop and a 180-trading-day horizon. This is a high-conviction, high-volatility trade…
Universal Health Services (UHS) has traded down from its 2025 highs and now sits at single-digit multiples with an EV/EBITDA under 6 and free cash flow near $900M. With behavioral health tailwinds and the Talkspace acquisition nearing close, the risk/reward looks favorable for a tactical long over the next 180 trading days.
A 20-year, $6.6 billion contracted lease for CleanSpark's Georgia campus materially derisks the company's move from bitcoin mining to AI data-center infrastructure. The deal gives predictable revenue visibility, but negative free cash flow, elevated leverage and a history of capital raises mean dilution risk is real. This trade buys the current wea…
Origin Bancorp (OBK) is trading near its 52‑week high on a market cap of roughly $1.75B. With a conservative balance sheet (debt/equity ~0.01), free cash flow of ~$164M and a diversified community‑banking franchise, the next 45 trading days offer a mid‑term opportunity to buy into Texas exposure and earnings momentum. Entry $55.00, stop $51.00, tar…
Valero is a high-quality refiner sitting on robust margins and cash generation, but near-term execution on throughput and repair timelines will decide whether the stock reclaims its recent highs. This trade idea outlines a mid-term long setup that buys a manageable pullback ahead of/after the Q2 report, with a disciplined stop and concrete target.
Helios Technologies combines mid-single-digit organic growth potential with decent free cash flow and a conservative balance sheet. At $75.06 the stock offers a GARP (growth at a reasonable price) entry for investors willing to ride a cyclical recovery in construction, agriculture and marine end markets, with an upside path back toward the prior 52…
Halozyme's hyaluronidase platform and growing royalty streams have pushed the company into sustained free-cash-flow generation and attractive forward earnings. With 2026 guidance raised—total revenue of $1.71-$1.81B and adjusted EBITDA of $1.125-$1.205B—Halozyme looks priced for continued re-rating. This trade idea lays out an actionable long with …
Ovintiv offers a practical way to play stable free-cash generation, a conservative balance sheet, and upside from natural gas and Montney scale. Valuation looks inexpensive on EV/EBITDA and price/book metrics while the company returns capital through a dividend and continued asset monetizations. We lay out an actionable mid-term trade with explicit…
Berkshire Hathaway trades with a notable gap between market value and the sum of its large cash balance plus marketable securities and operating businesses. With a $1.12T market cap, a roughly $397B cash pile and a ~$350B public equities sleeve, a conservative sum-of-the-parts implies upside if management accelerates buybacks or redeploys cash into…
Microsoft’s platform-first strategy (Nebius-style PaaS) continues to underpin durable revenue and cash flow even as Copilot and agentic product setbacks create headline volatility. The company’s cash generation, healthy balance sheet, and cloud positioning give investors a margin of safety. This trade idea targets a disciplined entry at $392 with a…
Alphabet is growing Google Cloud at an eye-popping clip (82% y/y) and is plowing enormous capital into AI infrastructure ($45B last quarter; plans for $811B more). The business is healthy, but the pace and scale of AI spending threatens near-term cash generation and valuation support. We lay out a tactical short trade with entry, stop and target fo…
Honeywell (HON) offers a way to play steadily improving aerospace aftermarket economics: a large installed base, double-digit ROE, solid free cash flow and a 4%+ yield combine to create an attractive risk/reward for a long trade. Technical momentum and manageable short interest add tactical support while valuation is reasonable versus cash generati…
Credo (CRDO) has seen a brisk sell-off from recent highs but its fiscal momentum (fiscal 2026 revenue > $1.3B, net income ~$472M), pristine balance sheet and AI-driven demand for connectivity argue the drop is overdone. This trade plan targets a mid-term swing (45 trading days) entry at $190.00 with a $240.00 target and a $168.00 stop.
Take-Two shares trade at $247.62 where a modest $65M misread of GTA 6's early monetization equals roughly $0.34 per share. That small-per-share gap understates how preorder confirmation, live-service economics, and an improving free cash flow profile can re-rate the stock. This trade targets a move to $265 within 45 trading days while maintaining a…
Belite Bio (BLTE) is a clinical-stage biotech with a differentiated oral candidate, tinlarebant, that completed a rolling NDA submission for Stargardt disease type 1 and has Phase 3 data showing a meaningful clinical effect. The company has near-term regulatory catalysts, a healthy cash position, and clear commercialization preparation. This trade …
LPKFF is an OTC-listed specialist where the trade is about future commercial adoption rather than today's numbers. Technicals show the stock under pressure but not deeply beaten; short interest and intraday short activity have been volatile. This trade plan uses a disciplined entry, clear stop and a mid-term horizon to capture a rebound if adoption…
